Retour à la liste des essais cliniquesBreast cancer

FAP-IT

68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

Ouvert à Saint-Cloud depuis le : 06/08/2024
Public cible : Adult
Phase : Phase II

Description de l'essai

To determine whether the Total FAP-expressing tumor burden TFTB, biomarker extracted from initial 68Ga-FAPI-46 PET-CT imaging, could accurately predict the histological response to treatment of patients with early-stage high-risk TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.

Url of the trial